Related Experiment Videos

Managing cutaneous reactions to imatinib therapy

Simon A J Rule, Stephen G O'Brien, Lucy C Crossman

|November 5, 2002

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.

Molecular cancer therapeutics·2019

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.

The Lancet. Haematology·2019

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.

The Lancet. Haematology·2017

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

The New England journal of medicine·2017

Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences.

British journal of haematology·2012

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).

Blood·2010

See all related articles